Jessica Weinstein, MD
Ophthalmology · Spokane, WANPI 1609212448
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 29.6% of the total. Reporting peaked in 2024 at $4,556 and has fallen 84.1% since, to $724 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $115.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$3K
- Alimera Sciences, Inc.$2K
- Regeneron$661
- AbbVie$659
- Astellas Pharma US Inc$536
- Regeneron Healthcare Solutions, Inc.$512
- plus $2K from 14 others
Across 24 payments — averaging $76.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$2K
- Boehringer Ingelheim$239
What the payments were for
- Consulting fees$1502%
- Speaking & faculty fees$3,09134%
- Travel & lodging$4985%
- Food & beverage$5,37059%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 11 | $2,698 |
| Alimera Sciences, Inc. | 9 | $1,805 |
| Regeneron | 5 | $661 |
| AbbVie(2 entities) | 9 | $659 |
| Astellas Pharma US Inc | 6 | $536 |
| Regeneron Healthcare Solutions, Inc. | 15 | $512 |
| Mallinckrodt Hospital Products Inc. | 3 | $360 |
| Genentech USA, Inc. | 5 | $318 |
| Dutch Ophthalmic, USA | 2 | $288 |
| Bausch & Lomb Americas Inc. | 2 | $239 |
| Eyepoint US, Inc. | 3 | $188 |
| Cardinal Health 110 LLC | 1 | $150 |
| Mallinckrodt Enterprises LLC | 1 | $129 |
| Rxsight Inc | 1 | $110 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $107 |
| Biogen | 1 | $105 |
| Novartis | 1 | $79 |
| Alcon | 1 | $78 |
| Genentech, Inc. | 1 | $65 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- YUTIQ$1,626
- Iluvien$1,626
- ACTHAR$489
- Syfovre$481
- EYLEA HD$379
- OZURDEX$340
- Izervay$272
- EVA Ophthalmic Surgical System$183
- VUITY$125
- DEXYCU$118
- RXSIGHT CONTACT LENS$110
- RXSIGHT INJECTOR CARTRIDGE$110
- LIGHT ADJUSTABLE LENS (LAL)$110
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$110
- RXSIGHT INJECTOR HANDPIECE$110
- STELLARIS PC$107
- EVA, combined machine$105
- TISSUEBLUE$105
How this compares
$9,110 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 102 | $4,866 |
| Atropine Sulfate | 89 | $2,687 |
| Difluprednate | 14 | $1,089 |
| ErythromycinErythromycin Base | 95 | $1,036 |
| Ofloxacin | 89 | $967 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $523 |
| Timolol Maleate | 22 | $378 |
| Brimonidine Tartrate | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Spokane
- Barbara SmitSpokane$110K
- Robert WirthlinSpokane$64K
- Gary FillmoreSpokane$6K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- Audrey RostovBellevue$155K
- John SamplesOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.